Analyst Price Target is $66.50
▲ +3,208.46% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Hoth Therapeutics in the last 3 months. The average price target is $66.50, with a high forecast of $100.00 and a low forecast of $33.00. The average price target represents a 3,208.46% upside from the last price of $2.01.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Hoth Therapeutics.
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.